Literature DB >> 28847452

Monetary conversion factors for economic evaluations of substance use disorders.

Kathryn McCollister1, Xuan Yang2, Bisma Sayed3, Michael T French4, Jared A Leff5, Bruce R Schackman6.   

Abstract

AIMS: Estimating the economic consequences of substance use disorders (SUDs) is important for evaluating existing programs and new interventions. Policy makers in particular must weigh program effectiveness with scalability and sustainability considerations in deciding which programs to fund with limited resources. This study provides a comprehensive list of monetary conversion factors for a broad range of consequences, services, and outcomes, which can be used in economic evaluations of SUD interventions (primarily in the United States), including common co-occurring conditions such as HCV and HIV.
METHODS: Economic measures were selected from standardized clinical assessment instruments that are used in randomized clinical trials and other research studies (e.g., quasi-experimental community-based projects) to evaluate the impact of SUD interventions. National datasets were also reviewed for additional SUD-related consequences, services, and outcomes. Monetary conversion factors were identified through a comprehensive literature review of published articles as well as targeted searches of other sources such as government reports.
RESULTS: Eight service/consequence/outcome domains were identified containing more than sixty monetizable measures of medical and behavioral health services, laboratory services, SUD treatment, social services, productivity outcomes, disability outcomes, criminal activity and criminal justice services, and infectious diseases consequences. Unit-specific monetary conversion factors are reported, along with upper and lower bound estimates, whenever possible.
CONCLUSIONS: Having an updated and standardized source of monetary conversion factors will facilitate and improve future economic evaluations of interventions targeting SUDs and other risky behaviors. This exercise should be repeated periodically as new sources of data become available to maintain the timeliness, comprehensiveness, and quality of these estimates.
Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cost-benefit analysis; Cost-effectiveness analysis; Economic consequences; Economic evaluation; Monetary conversion factors; Substance use disorders

Mesh:

Year:  2017        PMID: 28847452      PMCID: PMC5654317          DOI: 10.1016/j.jsat.2017.07.008

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  50 in total

1.  The economic cost of substance abuse treatment in the state of Florida.

Authors:  Pierre K Alexandre; Isabelle C Beulaygue; Michael T French; Kathryn E McCollister; Ioana Popovici; Bisma A Sayed
Journal:  Eval Rev       Date:  2012-06-17

2.  Benefit-cost in the California treatment outcome project: does substance abuse treatment "pay for itself"?

Authors:  Susan L Ettner; David Huang; Elizabeth Evans; Danielle Rose Ash; Mary Hardy; Mickel Jourabchi; Yih-Ing Hser
Journal:  Health Serv Res       Date:  2006-02       Impact factor: 3.402

3.  What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule?

Authors:  R Scott Braithwaite; David O Meltzer; Joseph T King; Douglas Leslie; Mark S Roberts
Journal:  Med Care       Date:  2008-04       Impact factor: 2.983

Review 4.  Costs of alcohol screening and brief intervention in medical settings: a review of the literature.

Authors:  Jeremy W Bray; Gary A Zarkin; Jesse M Hinde; Michael J Mills
Journal:  J Stud Alcohol Drugs       Date:  2012-11       Impact factor: 2.582

5.  Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement.

Authors:  Don Husereau; Michael Drummond; Stavros Petrou; Chris Carswell; David Moher; Dan Greenberg; Federico Augustovski; Andrew H Briggs; Josephine Mauskopf; Elizabeth Loder
Journal:  Value Health       Date:  2013 Mar-Apr       Impact factor: 5.725

6.  The lifetime medical cost savings from preventing HIV in the United States.

Authors:  Bruce R Schackman; John A Fleishman; Amanda E Su; Bethany K Berkowitz; Richard D Moore; Rochelle P Walensky; Jessica E Becker; Cindy Voss; A David Paltiel; Milton C Weinstein; Kenneth A Freedberg; Kelly A Gebo; Elena Losina
Journal:  Med Care       Date:  2015-04       Impact factor: 2.983

7.  The Economic Burden of Prescription Opioid Overdose, Abuse, and Dependence in the United States, 2013.

Authors:  Curtis S Florence; Chao Zhou; Feijun Luo; Likang Xu
Journal:  Med Care       Date:  2016-10       Impact factor: 2.983

8.  The global burden of chronic diseases: overcoming impediments to prevention and control.

Authors:  Derek Yach; Corinna Hawkes; C Linn Gould; Karen J Hofman
Journal:  JAMA       Date:  2004-06-02       Impact factor: 56.272

9.  The estimated direct medical cost of selected sexually transmitted infections in the United States, 2008.

Authors:  Kwame Owusu-Edusei; Harrell W Chesson; Thomas L Gift; Guoyu Tao; Reena Mahajan; Marie Cheryl Bañez Ocfemia; Charlotte K Kent
Journal:  Sex Transm Dis       Date:  2013-03       Impact factor: 2.830

10.  Integrated prevention services for HIV infection, viral hepatitis, sexually transmitted diseases, and tuberculosis for persons who use drugs illicitly: summary guidance from CDC and the U.S. Department of Health and Human Services.

Authors: 
Journal:  MMWR Recomm Rep       Date:  2012-11-09
View more
  13 in total

1.  Start-Up Costs of SBIRT Implementation for Adolescents in Urban U.S. Federally Qualified Health Centers.

Authors:  Carolina Barbosa; Brendan Wedehase; Laura Dunlap; Shannon Gwin Mitchell; Kristi Dusek; Robert P Schwartz; Jan Gryzcynski; Arethusa S Kirk; Marla Oros; Colleen Hosler; Kevin E O'Grady; Barry S Brown
Journal:  J Stud Alcohol Drugs       Date:  2018-05       Impact factor: 2.582

2.  Motivation to Change and Treatment Participation Among Syringe Service Program Utilizers in Rural Kentucky.

Authors:  Hilary L Surratt; Janet K Otachi; Timothy Williams; Jennifer Gulley; A Scott Lockard; Rebecca Rains
Journal:  J Rural Health       Date:  2019-08-15       Impact factor: 4.333

3.  Methadone, Buprenorphine, or Detoxification for Management of Perinatal Opioid Use Disorder: A Cost-Effectiveness Analysis.

Authors:  Ashish Premkumar; William A Grobman; Mishka Terplan; Emily S Miller
Journal:  Obstet Gynecol       Date:  2019-11       Impact factor: 7.661

4.  Cost and Cost-Effectiveness of Incentives for Viral Suppression in People Living with HIV.

Authors:  Laura J Dunlap; Stephen Orme; Gary A Zarkin; David R Holtgrave; Catherine Maulsby; Andrew M Rodewald; August F Holtyn; Kenneth Silverman
Journal:  AIDS Behav       Date:  2021-08-26

5.  Cost and Cost Savings of Navigation Services to Avoid Rehospitalization for a Comorbid Substance Use Disorder Population.

Authors:  Stephen Orme; Gary A Zarkin; Laura J Dunlap; Courtney D Nordeck; Robert P Schwartz; Shannon G Mitchell; Christopher Welsh; Kevin E O'Grady; Jan Gryczynski
Journal:  Med Care       Date:  2022-06-10       Impact factor: 3.178

6.  Cost-effectiveness of Hepatitis C Virus Treatment Models for People Who Inject Drugs in Opioid Agonist Treatment Programs.

Authors:  Sarah Gutkind; Bruce R Schackman; Jake R Morgan; Jared A Leff; Linda Agyemang; Sean M Murphy; Matthew J Akiyama; Brianna L Norton; Alain H Litwin; Benjamin P Linas
Journal:  Clin Infect Dis       Date:  2020-03-17       Impact factor: 20.999

7.  Improving retention across the OUD service cascade upon reentry from jail using Recovery Management Checkups-Adaptive (RMC-A) experiment.

Authors:  Christy K Scott; Michael L Dennis; Christine E Grella; Dennis P Watson
Journal:  J Subst Abuse Treat       Date:  2020-12-11

8.  Massachusetts Justice Community Opioid Innovation Network (MassJCOIN).

Authors:  Elizabeth A Evans; Thomas J Stopka; Ekaterina Pivovarova; Sean M Murphy; Faye S Taxman; Warren J Ferguson; Dana Bernson; Claudia Santelices; Kathryn E McCollister; Randall Hoskinson; Thomas Lincoln; Peter D Friedmann
Journal:  J Subst Abuse Treat       Date:  2021-01-08

9.  Interventions for female drug-using offenders.

Authors:  Amanda E Perry; Marrissa Martyn-St James; Lucy Burns; Catherine Hewitt; Julie M Glanville; Anne Aboaja; Pratish Thakkar; Keshava Murthy Santosh Kumar; Caroline Pearson; Kath Wright
Journal:  Cochrane Database Syst Rev       Date:  2019-12-13

Review 10.  Interventions for drug-using offenders with co-occurring mental health problems.

Authors:  Amanda E Perry; Marrissa Martyn-St James; Lucy Burns; Catherine Hewitt; Julie M Glanville; Anne Aboaja; Pratish Thakkar; Keshava Murthy Santosh Kumar; Caroline Pearson; Kath Wright; Shilpi Swami
Journal:  Cochrane Database Syst Rev       Date:  2019-10-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.